FLGT News and Press, Fulgent Genetics Inc. From 05/06/21

First Quarter 2021 Results : Record Revenue of $359.4 million, growing more than 4,500% year-over-year Record Billable tests delivered approximately 3.8 million, or 290 times the volume of first quarter of 2020 Gross Margin improved approximately 32 percentage points y...

Fulgent Genetics ([[FLGT]] -4.0%) appoints of Lawrence Weiss, M.D. as Chief Medical Officer, reporting to the CEO, Ming Hsieh. Dr. Weiss will be responsible for expanding Fulgent’s reach in molecular diagnostics and driving the advancement of the Company’...

Fulgent Genetics (NASDAQ:FLGT) is scheduled to announce Q1 earnings results on Thursday, May 6th, after market close.The consensus EPS Estimate is $5.70 (+19100.0% Y/Y) and the consensus Revenue Estimate is $321.51M (+4048.5% Y/Y).Over the last 2 years, FLGT has beaten EPS estimates 75% of th...

Shares of genetic testing company Fulgent Genetics (NASDAQ: FLGT) fell 20% in April, according to data from S&P Global Market Intelligence . Although that is up 475% from the beginning of 2020, the drop leaves the stock down 60% from its highs in February. Image ...

The Boyar Value Fund seeks long-term capital appreciation, which it pursues by investing primarily in equity securities of companies that are believed by the Fund's investment adviser to be intrinsically undervalued. Toward the end of the quarter, we saw one of the largest financial i...

Most strategy textbooks tell entrepreneurs they must choose between differentiating themselves with a superior product, great service, or the lowest cost to customers. That trade-off made more sense before software offered a way to achieve it all. Fulgent Genetics (NASDAQ: FLG...

The American Rescue Plan stimulus package includes $10 billion to be distributed to support COVID-19 testing in schools, plus another $2.5 billion to help state and local public health agencies increase testing in underserved and high-risk communities. And that's not all: Another $4 billion...

In a perfect world, companies classified as growth stocks would steadily improve their sales and earnings year after year, making no amount too expensive for their stock price. However, what ends up happening is that such companies often lose their trajectory due to a changing market or a...

The conference calls that follow a company's earnings report are rarely eventful. Usually, a few executives make a statement summarizing the performance of the business and then analysts ask questions. Occasionally, a comment will give shareholders insight into what the leadership team is r...

COVID has fully transformed this business. But investors need to answer what the underlying business, non-COVID revenue, looks like. Investors have no visibility into the profit margins of its non-COVID business. The stock appears to be cheap, but a lot of question marks remain as...